RNA Analysis Market Size, Share & Trends Analysis Report By Product (Instruments, Services), By Technology (qPCR, Microarray), By End-use (CROs, Hospitals & Clinics), By Application, And Segment Forecasts, 2021 - 2028

Report Overview

The global RNA analysis market size was valued at USD 9.28 billion in 2020 and is anticipated to expand at a compound annual growth rate (CAGR) of 13.44% from 2021 to 2028. The factors, such as are the rising demand for personalized medicine in cancer treatment and increasing R&D expenditure in transcriptomic technologies by pharmaceutical & biotechnology companies, are driving the growth of RNA analysis/transcriptomics market. In April 2021, Oxford Brookes University acknowledged the advancement of new single-cell transcriptomic technologies to analyze numerous individual cells from living organisms and sequence each cell’s genetic ingredient. As per the research, this method enables scientists to exchange the samples between labs, preserve the material, and can freeze the sample sets to analyze simultaneously without jeopardizing the quality of the cell.

The COVID-19 pandemic has created abundant opportunities for the market players. For instance, in June 2020, NanoString Technologies, Inc. launched the nCounter Host Response Gene Expression Panel for the study of immune system response during COVID-19 virus research. The product along with GeoMx Digital Spatial Profiler assisted the researchers in November 2021 study, to understand how COVID-19 did not infect olfactory sensory neurons in the patients.

In April 2021, Qiagen launched QIAseq DIRECT SARS-CoV-2 Kit, viral library preparation, and genome enrichment platform to reduce plastics use and library turnaround times as compared to primer-based sequencing. The company launched this product to cater to the increasing demand for high-throughput sequencing to carry out research and surveillance of novel and more hazardous variants of SARS-CoV-2.

The development and launch of novel products are anticipated to propel the market growth as it assists CROs to enhance the quality of research and aid pharmaceutical & biotechnology companies in vaccination development. For instance, in March 2021, Rebus Biosystems launched the spatial transcriptomics analysis platform theRebus Esper for spatial analysis of the transcriptome. This platform uses a laser-powered optic for high-resolution images and allows researchers to analyze individual cells.

Technology Insights

Based on technology, real-time-PCR (qPCR) technology dominated the market with the largest revenue share of more than 56% in 2020 due to increased use of PCR for COVID-19 diagnostic across the globe. The technology is considered to be highly sensitive and quantitative and one of the most suitable methods for interrogating a comparatively small number of transcripts in a broad set of samples. PCR offers relatively high-sensitivity detection of SARS-CoV-2, evaluation of viral RNA in various types of clinical samples, detecting SARS-CoV-2 mutations, and evaluation of anti-SARS-CoV-2 drugs. Thus, the COVID-19 pandemic served as a driving factor for the market.

Also, quantitative Real-Time PCR is employed to conduct a comparative analysis of transcriptome from the host and viral samples. The sequencing segment is anticipated to witness substantial growth over the forecast years owing to advancements in the next-generation and SMRT sequencing technology. The presence of several companies providing single-cell RNA sequencing services and the advent of bioinformatics algorithms are also driving the growth of this market.

Product Insights

Based on products, the kits & reagents segment accounted for the largest revenue share of over 58% in2020. Rising requirements for high-quality reagents and kits coupled with repeated use of reagents and media in transcriptome studies drive the segment growth. High-quality reagents and kits help deliver unmatched efficiency and strong performanceensures reliable &reproducible sequencing outcomes at a minimal cost.

Growing R&D activities in the pharmaceutical sector and increasing government investments in life science research are the major factors expected to fuel this market for consumables.NGS roots have begun with the adaptation of some SMART cDNA synthesis technology mainly for RNA-sequencing applications. RNA is now being implicated in a diverse number of biological processes, which include transcriptional regulation and catalysis.

Application Insights

The Infectious diseases and pathogenesis segment accounted for a substantial market share of more than 20% in 2020 and is closely followed by alternative RNA splicing applications. Identification of susceptible cells is crucial for understanding the pathogenic mechanism. Hence, scRNA-sequencing is increasingly adopted to provide information about cell types susceptible to infection. Next-generation sequencing is transforming the health approach to infectious diseases and pathogenesis, as well as treating individuals. Various methodologies have come for measuring gene expression and biomarkers for making their translation into clinical practice more feasible.

The RNA structure and molecular dynamics segment is expected to expand at a significant CAGR from 2021 to 2028 as pharmaceutical importance for RNA in the development of a new drug is gradually growing. In addition, molecular dynamics will also become a versatile tool to complement experimental investigations of RNA structural dynamics to provide opportunities for expanding the field and to maximize gains from the molecular dynamics simulations, without any further methodological advances.

End-use Insights

The government institutes & academic centers segment reported the highest revenue share of over 32% in 2020. The rising adoption of high throughput technologies for the effective process of RNA analysis by government institutes and academic centersis driving the segment growth. Increasing applications of transcriptomics technologies in drug discovery are majorly propelling the demand in the pharmaceutical as well as biotechnological industry.

Similarly, research in drug discovery is also contributing to the market that is followed by clinical diagnostics. For instance, in April 2021, researchers developed TORNADO-seq, an RNA sequencing-based drug discovery platform to monitor the expression of the large gene for a detailed study of cellular phenotypes in organoids.

In April 2021, The Italian Institute of Technology has signed a partnership agreement with European Molecular Biology Laboratory to expand their collaboration in research. This collaboration is anticipated to strengthen their database and share resources for the study. Recently, the Italian Institute of Technology introduced the RNA program focusing on non-coding RNAs.

Regional Insights

North America accounted for the maximum revenue share of more than 46% in 2020. The growth is attributed to the rapid development of structure-based drug designs, increasing focus on transcriptomics research, and high investment in biopharmaceutical research and development. In addition, increasing investment in pharmaceutical research and drug development is accelerating regional market growth.

Growing investments by governments &enterprises are accelerating biotechnology research in Asia Pacific countries. The Japanese government and non-government organizations are highly supportive of the growth of biotechnology research in the country and provide funds to research in the fields of medicine and life sciences. This encourages researchers to actively explore the transcriptomics space.

Furthermore, increasing focus on Asia Pacific countries is owing to the low-cost manufacturing services, is expected to provide growth opportunities for the manufacturers. The major players in this market have moved their focus to the emerging economies and initiated to develop a strong position in the market through different strategic initiatives, such as acquisitions.

Key Companies & Market Share Insights

The global market is highly fragmented with the presence of several small, mid, and large players that compete by adopting several organic growth strategies,such as product development and regional expansion, to enhance their market presence.For instance, in May 2021, Bio-Rad Laboratories Inc. had launched the latest offering of SEQuoiaRiboDepletion Kit, for Next-Generation (NGS) sequencing, which can improve assessment efficiency by eradicating irrelevant rRNA fragments from the RNA sequencing library.

Similarly, in May 2021, Thermo Fisher Scientific, Inc. had announced TaqPath SARS-CoV-2 CE-IVD RT-PCR Kit availability for international travel testing in the U.K. The kit is now entitled to clinics or laboratories in the surveillance. In addition, the PCR tests have been fundamental for testing against SARS-CoV-2 in the United Kingdom since the inception of the pandemic. Some key players operating in the global RNA analysis market include:

• Agilent Technologies, Inc.

• F. Hoffmann-La Roche AG

• Illumina, Inc.

• QIAGEN

• Thermo Fisher Scientific, Inc.

• Eurofins Scientific

• Merck KGaA

• Bio-Rad Laboratories, Inc.

• Pacific Bioscience of California, Inc.

• Affymetrix, Inc.

• Danaher Corporation

• Promega

RNA Analysis Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global RNA analysis market report on the basis of technology, product, application, end use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2028)

  • Real Time-PCR (qPCR) Technology

  • Microarray Technology

  • Sequencing Technology

  • Others

• Product Outlook (Revenue, USD Million, 2018 - 2028)

  • Instruments

  • Kits & Reagents

    • miRNA & siRNA

    • Reverse Transcriptases & RT-PCR

    • RNA Extraction & Purification

    • RNA Interference

    • Others

  • Services

• Application Outlook (Revenue, USD Million, 2018 - 2028)

  • Construction of RNA Expression Atlas

  • Epigenetics

  • Infectious Diseases and Pathogenesis

  • Alternative RNA Splicing

  • RNA Structure & Molecular Dynamics

  • Development & Delivery of RNA Therapeutics

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2028)

  • Government Institutes & Academic Centers

  • Pharmaceutical & Biotechnology Companies

  • Contract Research Organizations (CROs)

  • Hospitals & Clinics

• Regional Outlook (Revenue, USD Million, 2018 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Italy

    • Spain

    • France

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia